Currency effects hold back Takeda
This article was originally published in Scrip
Exchange rates knocked ¥20.7 billion ($218.6 million) off Takeda's top line in the first quarter to June 30th, dragging net sales down by around 5% to ¥379.0 billion.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.